Olumiant
<Program Title Pulled from
Approved Slide Deck>

INDICATION
Olumiant is a Janus kinase (JAK) inhibitor indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Limitation of Use: Use of Olumiant in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants, such as azathioprine and cyclosporine, is not recommended.

<day/month/year> | <XX:XX XM> | <Location>
<Event Venue Name>
<Venue Street Address> | <City, State Zip Code>

PROGRAM HIGHLIGHTS

Review JAK Pathway and MOA of Olumiant
Discuss Olumiant Efficacy Results
Review Important Safety Information for Olumiant
Examine Dosing and Administration for Olumiant

 

PRESENTED BY:

<Presenter Name, Credentials>
<Practice/Hospital Affiliation>
<City, State>
 
 
 
Sponsored by Lilly USA, LLC
 
-